仍進行中的收案
protocol number |
IRB No. |
protocol name |
sponsor |
CRO |
PI |
承接的SC |
PL001-NHL-201 |
2021-04-007C |
Phase 1/2 study of CD19 chimeric antigen |
Pell Bio-Med |
Parexel |
蕭樑材 |
黃淑香 |
NEOD001-301 |
2021-12-001A |
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis. |
Prothena |
ICONPRA |
劉耀中 |
黃淑香 |
C1071007 |
2022-04-003BU |
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE-POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION |
Pfizer |
Parexel |
劉嘉仁 |
陳薇光 |
M22-132 |
2022-08-002CU |
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma(BR/GemOx) |
AbbVie |
AbbVie |
蔡淳光 |
陳薇光 |
CA057-008 |
2022-08-018CU |
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480 (BMS-986348), Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) |
BMS |
NA |
劉嘉仁 |
陳薇光 |
2020年以前(已結束)
最後更新: